Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bfh-772. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 19/20 | 1.00 |
| ▸ | FLT1 | P17948 | 5/20 | 1.00 |
| ▸ | FLT4 | P35916 | 5/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 2/20 | 1.00 |
| ▸ | KIT | P10721 | 2/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.51 |
| ▸ | TNNI3K | Q59H18 | 3/20 | 0.51 |
| ▸ | BRAF | P15056 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bfh-772 SCHEMBL987715 | 1.00 | KDR (1.00) | KDRFLT1FLT4RETPDGFRB | |
| Bfh-772 SCHEMBL1041162 | 0.99 | KDR (0.98) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2465073 | 0.93 | KDR (0.87) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2435271 | 0.92 | KDR (0.85) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2434211 | 0.92 | KDR (0.85) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2439589 | 0.91 | KDR (0.83) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2468872 | 0.91 | KDR (0.83) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2438656 | 0.90 | KDR (0.81) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2437180 | 0.90 | KDR (0.81) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL1875161 | 0.89 | KDR (0.80) | KDRFLT1FLT4RETPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4539924-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS AND VEGF INHIBITORS | Novocure GmbH (CH) | 2025-04-23 | — | — | EP | claimed |
| CN-119451723-A | Compositions, systems, and methods for treating cancer using a tumor treating electric field and a VEGF inhibitor | 诺沃库勒有限责任公司 | 2025-02-14 | — | — | CN | claimed |
| WO-2023248139-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS AND VEGF INHIBITORS | NOVOCURE GMBH (CH) | 2023-12-28 | — | — | WO | claimed |
| US-20230405316-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS AND VEGF INHIBITORS | NOVOCURE GMBH (CH) | 2023-12-21 | — | — | US | claimed |
| CN-114585356-A | Methods of preventing or treating diseases associated with VEGFR and/or VEGF inhibition | 上海岸阔医药科技有限公司 | 2022-06-03 | — | — | CN | claimed |
| CN-114028568-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| CN-113975264-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-01-28 | — | — | CN | claimed |
| CN-122094689-A | Combination therapy of diacylglycerol kinase (DGK) alpha inhibitors with other therapies | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4739310-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-05-13 | — | — | EP | disclosed |
| US-12599664-B2 | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | NOVARTIS AG (CH) | 2026-04-14 | — | — | US | disclosed |
| US-12594331-B2 | Methods of treating psoriasis with secukinumab | NOVARTIS AG (CH) | 2026-04-07 | — | — | US | disclosed |
| US-12594332-B2 | Methods of treating psoriasis with secukinumab | NOVARTIS AG (CH) | 2026-04-07 | — | — | US | disclosed |
| US-20260083842-A1 | PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES | NOVARTIS AG (CH) | 2026-03-26 | — | — | US | disclosed |
| US-11351253-B2 | Methods of treating palmoplantar pustular psoriasis (PPP) using IL-17 antibody | NOVARTIS AG (CH) | 2022-06-07 | — | — | US | disclosed |
| CN-114585356-A | Methods of preventing or treating diseases associated with VEGFR and/or VEGF inhibition | 上海岸阔医药科技有限公司 | 2022-06-03 | — | — | CN | disclosed |
| EP-4003508-A1 | PERFUSION MODULATED TUMOR DOSE SCULPTING WITH SINGLE DOSE RADIOTHERAPY | Memorial Sloan Kettering Cancer Center (US) | 2022-06-01 | — | — | EP | disclosed |
| CN-114452381-A | Pharmaceutical product and stable liquid composition of IL-17 antibody | 诺华股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-114452380-A | Pharmaceutical product and stable liquid composition of IL-17 antibody | 诺华股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-114028568-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-02-11 | — | — | CN | disclosed |
| CN-113975264-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083842-A1 | PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES | IL17A, RAB7A, IL15 | KDR 2616/4885FLT1 2741/4885FLT4 1709/4885 |
| US-12599664-B2 | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | IL17A, IL15, IL5 | KDR 1367/4885FLT1 856/4885FLT4 598/4885 |
| US-12594332-B2 | Methods of treating psoriasis with secukinumab | IL17A, IL15, IL23R | KDR 535/4885FLT1 50/4885FLT4 86/4885 |
| US-12594331-B2 | Methods of treating psoriasis with secukinumab | IL17A, IL15, IL15RA | KDR 1107/4885FLT1 81/4885FLT4 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.